Navigation Links
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Date:9/15/2008

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel

macrolide-related drug class

WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile. The clinical development program for EDP-322 will include the treatment of hospital- and community-acquired gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Preclinically, EDP-322 has demonstrated strong in vitro activity against hospital-acquired MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

"Macrolides have been commonly prescribed to treat community infections for decades due to their convenient oral dosing and favorable safety profile," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now with the discovery of a new generation of macrolides having high potency against hospital-acquired pathogens and a distinct resistance profile relative to other hospital antibiotics, there is a tremendous new opportunity to explore their use within not only the community, but the hospital setting as well."

"In our in vitro studies, EDP-322 demonstrated good potency against both hospital- and community-acquired MRSA, even against highly drug-resistant MRSA strains," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "The potency of EDP-322 against hospital-acquired MRSA, community-acquired MRSA, and other gram-positive pathogens, combined with the convenience of oral administration, has the potential to uniquely position EDP-322 among marketed MRSA drugs in both the hospital and community settings."

<
'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
7. Isis Initiates Clinical Trial of CRP Drug
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156
10. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... to bump up their grade point averages during college, ... a library or study hall, but in a gym. ... who were members of the recreational sports and fitness ... years had higher GPAs than those who weren,t. ... stayed in school longer. An increase of 3.5 percent ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... that are just as tempting as full-fat equivalents ... fresh insights into how proteins can replace fats ... Funded by the Engineering and Physical Sciences Research ... the University of Edinburgh has produced modified proteins ... closely mimic the behaviour of fats during food ...
(Date:7/9/2014)... episodes of low back pain are not linked to ... direction and precipitation. Findings published in Arthritis Care ... of Rheumatology (ACR), indicate that the risk of low ... wind gusts, but was not clinically significant. , ... experiences low back pain at some point in their ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
Breaking Medicine News(10 mins):Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2
... and lack of proper sleep could be threatening thousands ... warns Heart and Stroke Foundation researcher Dr. Brian McCrindle, ... in Toronto. "Sleep disorders in kids are on ... other increasing cardiovascular risk factors such as overweight and ...
... 25, 2010 Young children who consume substantial amounts ... with fluoridated water or by swallowing fluoride toothpaste have ... to research published in the October issue of The ... supported by the National Institute of Dental and Craniofacial ...
... fear some of it unjustified are common among ... as MRSA, according to the results of a small study ... timely, detailed and simple information, the researchers add. ... Pediatrics , underscore the need for healthcare staff to do ...
... Reporter , MONDAY, Oct. 25 (HealthDay News) -- Why is ... the next day one person ends up feeling more tired ... in their genes, a new study suggests. Researchers at ... individuals who test positive for a common gene variant are ...
... Randy Dotinga HealthDay Reporter , MONDAY, Oct. 25 ... -- to be honest about their drug use, a new ... extent of drug use, but this new research finds that ... for drugs or they,re told the results will be confidential. ...
... treated with a combination of hormone therapy and radiation have ... do not receive radiation, according to interim results of the ... session, November 1, 2010, at the 52nd Annual Meeting of ... 1995 to 2005, 1,205 men with high-risk prostate cancer in ...
Cached Medicine News:Health News:Cardiac wakeup call for Canadian kids 2Health News:Cardiac wakeup call for Canadian kids 3Health News:Substantial consumption of fluoride increases chance of mild fluorosis 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 3Health News:How You Handle Lack of Sleep May Be in Your Genes 2Health News:How You Handle Lack of Sleep May Be in Your Genes 3Health News:Teens, Parents Often Lie About Illicit Drug Use 2Health News:Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances 2
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: